Skip to content

ImmunoCellular Therapeutics, Ltd.: 10-Q filed 2013-08-08

What ImmunoCellular Therapeutics, Ltd. reported in its quarterly report filed 2013-08-08 (fiscal Q2 2013): 29 published measures, 110 facts as tagged in accession 0001564590-13-000239.

This filing

Form
10-Q (quarterly report)
Filed
2013-08-08
Fiscal period
fiscal Q2 2013
Accession
0001564590-13-000239 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All ImmunoCellular Therapeutics, Ltd. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-06-3026,181,261USD
At 2012-12-3127,019,201USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-06-3023,046,604USD
At 2012-12-3123,068,014USD
At 2011-12-313,232,060USD
At 2010-12-312,335,830USD
At 2009-12-311,096,995USD
At 2008-12-312,940,336USD
At 2007-12-314,997,709USD
At 2006-12-31189,662USD
At 2005-12-3120,262USD
At 2004-12-31-11,494USD
At 2004-02-2497USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-06-3025,452,382USD
At 2012-12-3126,216,668USD
At 2012-06-3011,339,843USD
At 2011-12-316,653,168USD
At 2004-02-240USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-04-01 to 2013-06-30-150,329USD91
2013-01-01 to 2013-06-30-5,124,120USD181
2004-02-25 to 2013-06-30-46,200,450USD3414
2012-01-01 to 2012-12-31-14,495,139USD366
2012-04-01 to 2012-06-30-6,451,817USD91
2012-01-01 to 2012-06-30-14,341,252USD182
2011-01-01 to 2011-12-31-5,719,903USD365
2010-01-01 to 2010-12-31-6,150,142USD365
2009-01-01 to 2009-12-31-2,626,205USD365
2008-01-01 to 2008-12-31-3,059,730USD366
2007-01-01 to 2007-12-31-3,614,753USD365
2006-01-01 to 2006-12-31-5,152,713USD365
2005-01-01 to 2005-12-31-246,004USD365
2004-02-25 to 2004-12-31-11,741USD311

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-4,117,822USD181
2004-02-25 to 2013-06-30-32,661,796USD3414
2012-01-01 to 2012-06-30-6,889,220USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-06-3034,441USD181
2004-02-25 to 2013-06-30190,133USD3414
2012-01-01 to 2012-06-305,668USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2013-04-01 to 2013-06-300USD91
2013-01-01 to 2013-06-300USD181
2004-02-25 to 2013-06-30300,000USD3414
2012-04-01 to 2012-06-300USD91
2012-01-01 to 2012-06-300USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-06-303,387,977USD181
2004-02-25 to 2013-06-3058,329,311USD3414
2012-01-01 to 2012-06-3011,581,563USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-34,441USD181
2004-02-25 to 2013-06-30-215,133USD3414
2012-01-01 to 2012-06-30-5,668USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2013-06-30-48,292,950USD
At 2012-12-31-43,168,830USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2013-04-01 to 2013-06-300USD91
2013-01-01 to 2013-06-300USD181
2004-02-25 to 2013-06-300USD3414
2012-04-01 to 2012-06-300USD91
2012-01-01 to 2012-06-300USD182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-06-3085,229USD
At 2012-12-3176,289USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-06-30344,074USD181
2004-02-25 to 2013-06-308,997,930USD3414
2012-01-01 to 2012-06-30348,724USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-04-01 to 2013-06-30-2,181,936USD91
2013-01-01 to 2013-06-30-4,530,592USD181
2004-02-25 to 2013-06-30-43,891,463USD3414
2012-04-01 to 2012-06-30-3,130,572USD91
2012-01-01 to 2012-06-30-6,180,013USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-06-3025,854,457USD
At 2012-12-3126,931,176USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-06-30823,266USD
At 2012-12-311,098,307USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-06-30329,263USD
At 2012-12-31732,851USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-04-01 to 2013-06-301,213,570USD91
2013-01-01 to 2013-06-302,628,831USD181
2004-02-25 to 2013-06-3020,888,944USD3414
2012-04-01 to 2012-06-302,189,633USD91
2012-01-01 to 2012-06-304,188,169USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-06-3053,964,696shares
At 2012-12-3151,500,996shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-06-3071,334,158USD
At 2012-12-3166,231,694USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2013-06-30175,443USD
At 2012-12-31151,573USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2013-06-3090,214USD
At 2012-12-3175,284USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2013-06-30241,575USD
At 2012-12-3111,736USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-06-30202,869USD
At 2012-12-3156,111USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2013-04-01 to 2013-06-30-150,329USD91
2013-01-01 to 2013-06-30-5,124,120USD181
2004-02-25 to 2013-06-30-48,292,950USD3414
2012-04-01 to 2012-06-30-6,451,817USD91
2012-01-01 to 2012-06-30-14,341,252USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-04-01 to 2013-06-30788,420USD91
2013-01-01 to 2013-06-301,557,687USD181
2004-02-25 to 2013-06-3014,242,433USD3414
2012-04-01 to 2012-06-30837,322USD91
2012-01-01 to 2012-06-301,643,120USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-04-01 to 2013-06-3010,842USD91
2013-01-01 to 2013-06-3021,684USD181
2004-02-25 to 2013-06-3096,969USD3414
2012-04-01 to 2012-06-3011,444USD91
2012-01-01 to 2012-06-3022,888USD182

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2013-01-01 to 2013-06-3021,684USD181
2004-02-25 to 2013-06-3096,969USD3414
2012-01-01 to 2012-06-3022,888USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-403,588USD181
2004-02-25 to 2013-06-30328,913USD3414
2012-01-01 to 2012-06-30-560,266USD182

Inspect the source

Entity
ImmunoCellular Therapeutics, Ltd. / CIK 0000822411
Captured
SEC response SHA-256
0eba79ec53d6fb769bdb10da640228441bb5660977a2ac000a6d3fe9f3678be8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000822411.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))